Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly stops development of diabetes treatment

[Reuters] – Eli Lilly & Co said it stopped developing its experimental diabetes treatment after discussions with regulatory authorities and external experts. Lilly had delayed a marketing application for basal insulin … Read . . . → Read More: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly stops development of diabetes treatment Similar Articles: Company Update (NYSE:LLY): New Data Show Lilly’s Once-Weekly Trulicity® (dulaglutide) Solution for Injection is Effective as Add-on Treatment to Sulfonylurea Company Update (NYSE:LLY): Yabao Pharmaceuticals Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment Market Update: Eli Lilly & Company (NYSE:LLY) – EXCLUSIVE-US insurers hold back Lilly’s death-defying diabetes drug